Business Context and Reporting Period
This Form 8-K was filed by Trovagene, Inc. (not Cardiff Oncology, Inc.) on December 14, 2017. The report covers a specific corporate event occurring on the same date regarding the company's clinical development activities.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a regulatory milestone rather than financial performance.
Material Changes
On December 14, 2017, Trovagene, Inc. submitted a protocol to the U.S. Food and Drug Administration (FDA) for review. The protocol outlines a Phase 2 clinical trial for the investigational drug PCM-075 in combination with abiraterone acetate (Zytiga) for the treatment of metastatic Castration-Resistant Prostate Cancer (mCRPC).
Guidance, Outlook, and Risks
The filing does not contain financial guidance, management commentary on future earnings, or specific risk factors beyond the inherent uncertainties of clinical trial approvals. The primary focus is the submission of the clinical trial protocol.
Investor Verification Checklist
- Verify the registrant name is Trovagene, Inc., not Cardiff Oncology, Inc.
- Confirm the status of the FDA review for the PCM-075 Phase 2 trial protocol.
- Review the full press release (Exhibit 99.1) for details on the trial design and patient population.
- Check subsequent filings for updates on the FDA's response to the protocol submission.